文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肺微生物组作为慢性呼吸疾病的可治疗特征。

Lung Microbiome as a Treatable Trait in Chronic Respiratory Disorders.

机构信息

Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.

CEINGE-Biotecnologie Avanzate-Franco Salvatore, Naples, Italy.

出版信息

Lung. 2023 Oct;201(5):455-466. doi: 10.1007/s00408-023-00645-3. Epub 2023 Sep 26.


DOI:10.1007/s00408-023-00645-3
PMID:37752217
Abstract

Once thought to be a sterile environment, it is now established that lungs are populated by various microorganisms that participate in maintaining lung function and play an important role in shaping lung immune surveillance. Although our comprehension of the molecular and metabolic interactions between microbes and lung cells is still in its infancy, any event causing a persistent qualitative or quantitative variation in the composition of lung microbiome, termed "dysbiosis", has been virtually associated with many respiratory diseases. A deep understanding of the composition and function of the "healthy" lung microbiota and how dysbiosis can cause or participate in disease progression will be pivotal in finding specific therapies aimed at preventing diseases and restoring lung function. Here, we review lung microbiome dysbiosis in different lung pathologies and the mechanisms by which these bacteria can cause or contribute to the severity of the disease. Furthermore, we describe how different respiratory disorders can be caused by the same pathogen, and that the real pathogenetic mechanism is not only dependent by the presence and amount of the main pathogen but can be shaped by the interaction it can build with other bacteria, fungi, and viruses present in the lung. Understanding the nature of this bacteria crosstalk could further our understanding of each respiratory disease leading to the development of new therapeutic strategies.

摘要

曾经被认为是无菌的环境,现在已经确定肺部存在着各种微生物,这些微生物参与维持肺功能,并在塑造肺部免疫监视方面发挥着重要作用。尽管我们对微生物和肺细胞之间的分子和代谢相互作用的理解还处于起步阶段,但任何导致肺部微生物组组成发生持续的定性或定量变化的事件,即“失调”,几乎都与许多呼吸道疾病有关。深入了解“健康”肺部微生物组的组成和功能,以及失调如何导致或参与疾病进展,对于寻找旨在预防疾病和恢复肺功能的特定治疗方法至关重要。在这里,我们综述了不同肺部病理中的肺部微生物组失调以及这些细菌如何导致或加重疾病的机制。此外,我们还描述了不同的呼吸障碍如何由同一病原体引起,并且真正的发病机制不仅取决于主要病原体的存在和数量,还可以通过它与肺部其他细菌、真菌和病毒的相互作用来塑造。了解这种细菌相互作用的性质可以进一步加深我们对每种呼吸道疾病的理解,从而为开发新的治疗策略提供依据。

相似文献

[1]
Lung Microbiome as a Treatable Trait in Chronic Respiratory Disorders.

Lung. 2023-10

[2]
The Human Respiratory Microbiome: Implications and Impact.

Semin Respir Crit Care Med. 2018-3-26

[3]
Crosstalk between the lung microbiome and lung cancer.

Microb Pathog. 2023-5

[4]
The possible mechanisms of the human microbiome in allergic diseases.

Eur Arch Otorhinolaryngol. 2017-2

[5]
The pulmonary microbiome: challenges of a new paradigm.

J Bras Pneumol. 2018

[6]
Lupus: The microbiome angle.

Immunobiology. 2018

[7]
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.

Microbiol Spectr. 2015-6

[8]
Respiratory tract microbiome and pneumonia.

Prog Mol Biol Transl Sci. 2022

[9]
Persistent Legionnaires' Disease and Associated Antibiotic Treatment Engender a Highly Disturbed Pulmonary Microbiome Enriched in Opportunistic Microorganisms.

mBio. 2020-5-19

[10]
Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.

Front Immunol. 2020

引用本文的文献

[1]
Respiratory microbiota diversity and composition in recurrent protracted bacterial bronchitis: a cross-sectional study.

Front Cell Infect Microbiol. 2025-7-28

[2]
A mass spectrometry-based strategy for investigating volatile molecular interactions in microbial consortia: unveiling a -specific induction of an antifungal compound.

Front Microbiol. 2025-2-25

[3]
Tyndallized bacteria prime bronchial epithelial cells to mount an effective innate immune response against infections.

Hum Cell. 2024-7

[4]
LUNG Year in Review: 2023.

Lung. 2024-2

本文引用的文献

[1]
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.

Eur Respir J. 2023-4

[2]
Microbiome and Asthma: Microbial Dysbiosis and the Origins, Phenotypes, Persistence, and Severity of Asthma.

Nutrients. 2023-1-17

[3]
Relationship Between COPD and GERD: A Bibliometrics Analysis.

Int J Chron Obstruct Pulmon Dis. 2022

[4]
Genetic Adaptation and Acquisition of Macrolide Resistance in Haemophilus spp. during Persistent Respiratory Tract Colonization in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Long-Term Azithromycin Treatment.

Microbiol Spectr. 2023-2-14

[5]
The dynamic lung microbiome in health and disease.

Nat Rev Microbiol. 2023-4

[6]
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis.

Am J Respir Crit Care Med. 2023-4-1

[7]
Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients.

Life (Basel). 2022-7-28

[8]
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review.

Cancers (Basel). 2022-6-26

[9]
COPD and Gut-Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics.

Front Microbiol. 2022-4-1

[10]
The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment.

Lung Cancer. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索